RT Journal Article
SR Electronic
T1 A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5393
OP 5397
DO 10.21873/anticanres.14547
VO 40
IS 10
A1 SUGISAWA, NORIHIKO
A1 NISHINO, HIROTO
A1 HIGUCHI, TAKASHI
A1 PARK, JUN HO
A1 YAMAMOTO, JUN
A1 TASHIRO, YOSHIHIKO
A1 KAWAGUCHI, KEI
A1 BOUVET, MICHAEL
A1 UNNO, MICHIAKI
A1 HOFFMAN, ROBERT M.
YR 2020
UL http://ar.iiarjournals.org/content/40/10/5393.abstract
AB Background/Aim: We established a new patient-derived orthotopic xenograft (PDOX) model of gastric cancer liver metastasis and evaluated the efficacy of a novel combination chemotherapy, gemcitabine (GEM) plus 5-fluorouracil (5-FU), compared to a standard regimen of oxaliplatinum (L-OHP) plus 5-FU on the liver metastasis. Materials and Methods: Patient-derived gastric cancer was established in nude mice from the patient' s surgical tumor specimen. A single tumor fragment was implanted in the liver of nude mice. The mice with tumors were treated by GEM plus 5-FU or L-OHP plus 5-FU. Results: GEM plus 5-FU or L-OHP plus 5-FU significantly and similarly inhibited tumor growth on the liver compared to the untreated control (p=0.007, p=0.02, respectively). Conclusion: GEM plus 5-FU could be a novel future clinical alternative to L-OHP plus 5-FU in gastric cancer patients who cannot tolerate platinum drugs.